کد مقاله | کد نشریه | سال انتشار | مقاله انگلیسی | نسخه تمام متن |
---|---|---|---|---|
4350125 | 1296974 | 2006 | 4 صفحه PDF | دانلود رایگان |

Currently, neurochemical dementia diagnostics (NDD) are increasingly entering routine clinical neurochemistry, offering improved early and differential diagnosis of dementias. However, there is an obvious lack of standardization in pre-analytical sample handling and systematic quality surveys. Therefore, in this study, 14 laboratories in Germany, Austria, and Switzerland were given aliquots of a human cerebrospinal fluid (CSF) sample, and were asked to measure Alzheimer's disease (AD) biomarkers (amyloid β (Aβ) peptides, total Tau protein, and phosphorylated Tau protein (P-tau181P)) according to their routine protocols. Results: The inter-laboratory coefficients of variation of the results obtained by the laboratories participating in this study were in the range of 20–30%. Although the results of this quality control survey are promising, the quality of measurements has to be further optimized.
Journal: Neuroscience Letters - Volume 409, Issue 1, 27 November 2006, Pages 1–4